DNDi’s interventions at the 72nd World Health Assembly.
1 February 2019
A new research paper recently published by the AFD (Agence Française de Développement) examines how DNDi, a distinctive Product Development Partnership (PDP), can illustrate what can be presented as a “commons” in the area of public health.
DNDi had 4 interventions planned at the 144th session of the WHO Executive Board.
23 January 2019
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 33 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.
15 November 2018
On November 15, 2018, members of the Chagas Clinical Research Platform and the Global Chagas Coalition, participating in the VIII Meeting of the Chagas Platform in Santa Cruz de la Sierra, Bolivia, signed this letter addressed to governments, organizations and donors requesting an intensification in the efforts to control and eliminate Chagas disease as a public health problem. In the last 10 years, there have been significant efforts in the fight against the disease. However, many challenges remain. Next 2019 marks the 110th anniversary since the discovery of the disease and constitutes an opportunity to call attention to people affected by the disease and pursue necessary actions.
To help inform the Canadian government’s approach to biomedical innovation, particularly as relates to innovations of public health importance, DNDi has submitted a contribution providing concrete evidence of DNDi’s experience implementing needs-driven, open, collaborative R&D. The contribution recommends a series of progressive policy steps Canada can support to re-orient the global biomedical R&D system so that it (1) prioritizes patient and public health needs; (2) is sustainably financed; and (3) incorporates global norms that will enable the discovery, development, and delivery of and equitable access to innovations of public health importance.
10 September 2018
As a contribution to the World Health Organization roadmap on access to medicines and vaccines, Dr Bernard Pécoul noted the importance of including concrete deliverables in the short-, medium-, and long-term, including prioritization of R&D, open and collaborative approaches to innovation, regulatory infrastructure, and solving gaps in diagnostics and specific needs of children.
24 May 2018
DNDi and MMV, supported by Unitaid, delivered a statement on the progress made by WHO in developing a Global Framework on Nurturing Care for Early Childhood Development. The statement calls for R&D and access to child-friendly medicines, and open data sharing of research findings.
27 January 2018
Medicines for Malaria Venture and DNDi delivered a joint statement at WHO’s Executive Board 142, urging WHO to recognize the urgent need for research and development, access, and uptake of child-friendly medicines.
May 10-11, 2017
Amsterdam, The Netherlands
Organized by the World Health Organization in collaboration with the Dutch Ministry of Health, the Fair Pricing Forum was held to discuss options for a fairer pricing system, that is sustainable for both health systems and innovation challenges to access and how to move forward.
DNDi participated in the event.
[21 September, 2016]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the commitment made by world leaders today at the United Nations (UN) General Assembly to address one of the world’s most pressing public health issues, antimicrobial resistance (AMR).
[14 September, 2016]
The Drugs for Neglected Diseases initiative (DNDi) today welcomes the release of the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines. The Panel has clearly confirmed the policy misalignment between intellectual property and trade rules, international human rights obligations, and public health objectives. It has underlined many immediate access challenges and steps that must be taken to overcome them, and highlighted that existing funding and incentive mechanisms are not adequate to stimulate innovation to address global public health needs.
[6 June, 2016]
The Access to Medicine Foundation report explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of research & development (R&D) models in incentivizing these contributions. For the past 10 years, the Access to Medicine Foundation has tracked the progress of pharmaceutical engagement in R&D for neglected diseases, they found that models like Product Development Partnerships (PDPs) have been highly successful in creating incentives for pharmaceutical companies to participate in access-friendly R&D.
[27 May, 2016]
At the 69th WHA, Member States were asked to consider the outcomes of the Open-Ended Meeting and continue discussions on issues related to monitoring, coordination and financing for health research. Michelle Childs, DNDi‘s Head of Policy Advocacy, delivered the following statement on behalf of DNDi.
[2 May, 2016]
A DNDi Intervention was presented by Bernard Pécoul at this open-ended meeting by Member States on CEWG.
[27 February, 2016]
The proposed objective of the UN Secretary General’s High-Level Panel on Access to Medicines is to review and assess proposals and recommend solutions for remedying the policy incoherence between the rights of inventors, international human rights law, trade rules and public health in the context of health technologies. DNDi submitted a formal contribution.
[23 February, 2016]
DNDi attended the 138th Executive Board of the World Health Organization. The Executive Board was considering a resolution to add the mycetoma to WHO’s official list of neglected diseases.The mycetoma resolution will be proposed for adoption at the upcoming World Health Assembly agenda in May.
[22 May, 2015]
Alexandra Heumber, DNDi‘s Head of Policy Affairs, delivered a statement on behalf of DNDi at the 68th World Health Assembly (WHA).
A new paper recently commissioned by DNDi examines the possibilities of creating a pooled international R&D fund for the Demonstration Projects that were selected as part of the process following on the report of the WHO Consultative Expert Working Group on Research and Development (CEWG): “Demonstration Financing: Considerations for a Pilot Pooled International Fund for R&D.”
To mark its 10 year anniversary, DNDi has issued a report that explores the lessons learned from a decade of research and development (R&D) of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model.